+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lemtrada"

From
Multiple Sclerosis Drugs Market Report 2026 - Product Thumbnail Image

Multiple Sclerosis Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Multiple Sclerosis - Competitive Landscape, 2026 - Product Thumbnail Image

Multiple Sclerosis - Competitive Landscape, 2026

  • Report
  • January 2026
  • 280 Pages
  • Global
From
From
From
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Lemtrada is a brand name for alemtuzumab, a monoclonal antibody used to treat multiple sclerosis (MS). It is a type of central nervous system (CNS) drug, which are used to treat a variety of neurological conditions. Lemtrada is used to reduce the frequency of relapses in people with relapsing-remitting MS, and to slow the progression of disability. It is administered as an intravenous infusion over two or three days. The Lemtrada market is made up of pharmaceutical companies that produce and market the drug. These companies are involved in research and development, manufacturing, and marketing of the drug. They also provide support services to healthcare professionals and patients. Some companies in the Lemtrada market include Sanofi, Bayer, Biogen, Merck, and Novartis. Show Less Read more